Acute encephalopathy with biphasic seizures and late reduced diffusion in a Spanish girl

Miguel García-Boyano1, José Manuel Caballero-Caballero1, Marina Alguacil-Guillén1

  • 1Hospital Universitario La Paz, Madrid, Spain.

Brain & Development
|January 30, 2020
PubMed

Insights

This case study details acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) in a child. Procalcitonin and CRP levels, along with MR spectroscopy, aided early diagnosis and outcome prediction.

Area of Science:

  • Neurology
  • Pediatrics
  • Infectious Diseases

Background:

  • Acute encephalopathy with biphasic seizures and late reduced diffusion (AESD) is a rare neurological condition.
  • Early diagnosis and understanding of AESD are crucial for patient outcomes.
  • Biomarkers and neuroimaging play a key role in diagnosing and managing neurological disorders in children.

Observation:

  • A 22-month-old Spanish girl presented with AESD, characterized by biphasic seizures and later diffusion restriction on MRI.
  • Serum procalcitonin (PCT) levels peaked at 50.5 ng/mL on day 1, and C-reactive protein (CRP) peaked at 1.21 mg/dL on day 2.
  • Neurological examination at discharge revealed persistent right spastic hemiparesis.

Findings:

  • Magnetic resonance (MR) spectroscopy on day 23 showed decreased N-acetylaspartate and increased choline, indicating neuronal injury.
  • The study highlights the potential utility of PCT and the PCT/CRP ratio in the early diagnosis of AESD.
  • Correlation between MR spectroscopy findings and long-term neurological outcomes was observed.

Implications:

  • This case represents the first reported instance of AESD in Europe.
  • The findings suggest that PCT and CRP can serve as valuable early diagnostic markers for AESD.
  • MR spectroscopy findings may help predict neurological deficits in patients with AESD, guiding clinical management and prognosis.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.2K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
548
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
743